Ulrich Laufs is Chair and Professor of Cardiology at Leipzig University, Germany. After completing his training at the University of Hamburg, he served a residency at the University of Cologne and spent 2 years as post-doctoral researcher at the Brigham and Women’s Hospital in Boston, USA.  Before moving to Leipzig in 2017, he was Vice-chairman of the Department of Internal Medicine, Cardiology, Angiology and Intensive Medicine at the University of Saarland in Homburg, Germany.

Professor Laufs has published multiple experimental and clinical studies in the areas of ‘heart failure’, ‘heart and brain’ and ‘prevention’ with special interest in lipoprotein metabolism. He has received numerous honours, serves in several editorial boards of international cardiovascular journals and holds positions in cardiovascular societies.

Contributions

Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention - Discussion and Q&A90th EAS Congress 2022ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemiaWhat is new in secondary prevention?90th EAS Congress 2022ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemiaLCN Workshop on Clinical Lipidology - GermanyWebinars on-demand(DyslipidemiaReviewReviewLipidologyTreatmentPrimary HyperlipidemiaHypolipidemic drugs)A tale of two trials89th EAS Congress 2021(TreatmentTriglycerideLC Omega 3 fatty acidsCVOTHypolipidemic drugs)Ongoing studiesIntro to Clinical LipidologyCurrent available therapies - PCSK9 inhibitionIntro to Clinical LipidologyGuidelines - ACS & very highrisk patientsAn Introduction to Clinical LipidologyWhen do we need add on therapies to statin?88th EAS Congress 2020(Anti PCSK9ReviewReviewReviewGuidelinesCholesterolTreatmentEzetimibeStatinesHypolipidemic drugs)Reality check - Can we get to goals in guidelines?86th EAS Congress 2018